EFICÁCIA E SEGURANÇA DA CLOZAPINA E DA OLANZAPINA NA ESQUIZOFRENIA RESISTENTE AO TRATAMENTO: UMA REVISÃO INTEGRATIVA
DOI:
https://doi.org/10.71248/q8tk7462Palavras-chave:
Antipsychotic Agents, Clozapine, Drug Resistence, Electroconvulsive Therapy, Olanzepine, SchizophreniaResumo
A esquizofrenia resistente ao tratamento representa um desafio clínico e de saúde pública, especialmente pela persistência dos sintomas após falha terapêutica com pelo menos dois antipsicóticos. Objetivo: analisar a literatura acerca da eficácia, segurança, efeitos adversos e custo-benefício da clozapina e da olanzapina no tratamento da esquizofrenia resistente. Métodos: realizou-se uma revisão com busca sistematizada na base Epistemonikos, utilizando a estratégia treatment AND schizophrenia AND clozapina OR olanzapina. Foram encontrados 419 resultados iniciais e, após aplicação de filtros, 29 artigos foram selecionados para análise. Resultados e discussão: os estudos indicam que a clozapina permanece como padrão-ouro para a esquizofrenia resistente, apresentando superioridade clínica e redução de internações hospitalares. Entretanto, exige monitoramento rigoroso devido a efeitos adversos como hipersonolência, constipação, taquicardia e risco de toxicidade em infecções. A olanzapina mostrou eficácia em quadros agudos, porém com importante limitação por efeitos metabólicos. Estratégias como metformina, topiramato e eletroconvulsoterapia podem auxiliar em casos específicos. Conclusão: a clozapina é a principal alternativa terapêutica para a esquizofrenia resistente, desde que acompanhada de vigilância clínica, manejo de efeitos adversos e suporte estruturado nos serviços de saúde.
Referências
QUILES, C.; TAILLARD, J.; LOPEZ, R.; GEOFFROY, P. A.; SALVO, F.; MICOULAUD-FRANCHI, J.-A. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review. Journal of Sleep Research, v. 34, n. 3, e14360, 2025. DOI: https://doi.org/10.1111/jsr.14360.
SAMARA, M. T. et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, v. 73, n. 3, p. 199-210, 2016. DOI: https://doi.org/10.1001/jamapsychiatry.2015.2955.
BAI, Z. et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophrenia Research, v. 185, p. 73-79, 2017. DOI: https://doi.org/10.1016/j.schres.2017.01.002.
PAGSBERG, A. K. et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry, v. 56, n. 3, p. 191-202, 2017. DOI: https://doi.org/10.1016/j.jaac.2016.12.013.
SISKIND, D. et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry, v. 209, n. 5, p. 385-392, 2016. DOI: https://doi.org/10.1192/bjp.bp.115.177261.
GÖREN, J. L. et al. The business case for expanded clozapine utilization. Psychiatric Services, v. 67, n. 11, p. 1197-1205, 2016. DOI: https://doi.org/10.1176/appi.ps.201500507.
MEHTA, T. M.; VAN LIESHOUT, R. J. A review of the safety of clozapine during pregnancy and lactation. Archives of Women’s Mental Health, v. 20, n. 1, p. 1-9, 2017. DOI: https://doi.org/10.1007/s00737-016-0670-0.
LALLY, J. et al. Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database of Systematic Reviews, n. 6, CD011566, 2016. DOI: https://doi.org/10.1002/14651858.CD011566.pub2.
CLARK, S. R. et al. Elevated clozapine levels associated with infection: a systematic review. Schizophrenia Research, v. 192, p. 50-56, 2018. DOI: https://doi.org/10.1016/j.schres.2017.03.045.
KRIVOY, A. et al. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. International Clinical Psychopharmacology, v. 31, n. 4, p. 179-184, 2016. DOI: https://doi.org/10.1097/YIC.0000000000000065.
MOUCHLIANITIS, E. et al. Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. The Lancet Psychiatry, v. 3, n. 5, p. 451-463, 2016. DOI: https://doi.org/10.1016/S2215-0366(15)00540-4.
KHUSHU, A.; POWNEY, M. J. Haloperidol for long-term aggression in psychosis. Cochrane Database of Systematic Reviews, v. 11, n. 11, CD009830, 2016. DOI: https://doi.org/10.1002/14651858.CD009830.pub2.
GILLESPIE, A. L. et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry, v. 17, n. 1, artigo 12, 2017. DOI: https://doi.org/10.1186/s12888-016-1177-y.
BARBER, S. et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database of Systematic Reviews, v. 3, n. 3, CD006324, 2017. DOI: https://doi.org/10.1002/14651858.CD006324.pub3.
JIMÉNEZ-CORNEJO, M. et al. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia? Medwave, v. 16, supl. 5, e6614, 2016. DOI: https://doi.org/10.5867/medwave.2016.6614.
REYES, H. Q. et al. Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia. Revista Colombiana de Psiquiatría, v. 45, n. 2, p. 67-74, 2016. DOI: https://doi.org/10.1016/j.rcp.2015.05.013.
LALLY, J. et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, v. 171, n. 1-3, p. 215-224, 2016. DOI: https://doi.org/10.1016/j.schres.2016.01.024.
KITTSTEINER MANUBENS, L. et al. Is electroconvulsive therapy effective as augmentation in clozapine-resistant schizophrenia? Medwave, v. 16, supl. 5, e6577, 2016. DOI: https://doi.org/10.5867/medwave.2016.6577.
SUBRAMANIAN, S. et al. Clozapine dose for schizophrenia. Cochrane Database of Systematic Reviews, v. 6, n. 6, CD009555, 2017. DOI: https://doi.org/10.1002/14651858.CD009555.pub2.
LAND, R. et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica, v. 135, n. 4, p. 296-309, 2017. DOI: https://doi.org/10.1111/acps.12700.
SISKIND, D. J. et al. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLOS ONE, v. 11, n. 6, e0156208, 2016. DOI: https://doi.org/10.1371/journal.pone.0156208.
REVILLA-ZÚÑIGA, J.; SAGÁSTEGUI-SOTO, A.; CARAZAS-VERA, M.; SAAVEDRA-CASTILLO, A. Revisión actualizada de recomendaciones para el tratamiento de la esquizofrenia en un instituto especializado: enfoque en terapias farmacológicas y psicosociales. Revista de Neuro-Psiquiatría, v. 88, n. 2, p. 147-156, 2025. Disponível em: https://revistas.upch.edu.pe/index.php/RNP/article/view/6248. Acesso em: 14 maio 2026.
ORTIZ-ORENDAIN, J. et al. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews, v. 6, n. 6, CD009005, 2017. DOI: https://doi.org/10.1002/14651858.CD009005.pub2.
ZHENG, W. et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatrica Scandinavica, v. 134, n. 5, p. 385-398, 2016. DOI: https://doi.org/10.1111/acps.12631.
ELECTROCONVULSIVE therapy alone for schizophrenia: a meta-analysis of randomized, single-blind, controlled trials: retraction. The Journal of ECT, v. 32, n. 4, p. 275, 2016. DOI: https://doi.org/10.1097/YCT.0000000000000353.
PERESTRELO, J.; TEIXEIRA, B. Psychogenic polydipsia and hyponatremia: a side effect of psychosis: a review with a case report. Jornal Brasileiro de Psiquiatria, v. 65, n. 3, p. 300-303, 2016. DOI: https://doi.org/10.1590/0047-2085000000135.
CORRELL, C. U. et al. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized controlled trials. The Journal of Clinical Psychiatry, v. 77, n. 6, p. e746-e756, 2016. DOI: https://doi.org/10.4088/JCP.15r10373.
RATTEHALLI, R. D. et al. Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, v. 12, n. 12, CD006918, 2016. DOI: https://doi.org/10.1002/14651858.CD006918.pub3.
EVERY-PALMER, S. et al. Pharmacological treatment for antipsychotic-related constipation. Cochrane Database of Systematic Reviews, v. 1, n. 1, CD011128, 2017. DOI: https://doi.org/10.1002/14651858.CD011128.pub2.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2026 Cognitus Interdisciplinary Journal
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
